• About
    • Awards
    • History
    • Leadership
    • Board of Directors
    • Investors and Partners
  • Pipeline
    • Cefepime-Taniborbactam
    • Ceftibuten / VNRX-7145
    • PBP Inhibitor
    • VNRX-9945
  • Publications
    • Manuscripts
    • Conference Presentations
  • News & Events
    • Press Releases
    • In the News
    • Events
  • Careers
    • Open Positions
    • #venatorxcares
  • Contact
Publications
  • Publications
  • Manuscripts
  • Conference Presentations

Manuscripts

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
Bronchopulmonary disposition of IV cefepime/taniborbactam (2–0.5 g) administered over 2 h in healthy adult subjects
MORE MANUSCRIPTS

Conference Presentations

In Vitro Activity of Cefepime-Taniborbactam and Comparators against a Global Collection of Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) with and without Carbapenemases
Activities of Cefepime-Taniborbactam and Ceftazidime-Avibactam against Cefepime-Resistant Respiratory Gram-Negative Pathogens in a Hollow Fiber Infection Model
Development of Cefepime-Taniborbactam MIC Antimicrobial Susceptibility Test for Gram-Negative Bacteria on MicroScan Dried Gram-Negative MIC Panels
Antimicrobial Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates from ICU and Non-ICU Patients; 2018-2020 Global Surveillance
MORE CONFERENCE PRESENTATIONS
  • ©2023 Venatorx Pharmaceuticals, Inc.
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
  • Sitemap
You are using a browser that is not supported. Please consider changing your browser